CTOs on the Move

Lineage Cell

www.lineagecell.com

 
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage`s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage`s clinical assets include (i) OpRegen®, a retinal pigment epithelium ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Funding

Lineage Cell raised $35.9M on 03/08/2021

Similar Companies

54gene

54gene was founded in 2019 by Dr. Abasi Ene-Obong to address the significant gap in the global genomics market; Nearly 90% of genetic material used in pharmaceutical research is Caucasian. Only 2% is African, despite the fact that Africans and people of African ancestry are more genetically diverse than all other world populations combined. As a result, pharmaceutical research and development is lacking the diverse data that may hold the key to medical discoveries and new healthcare solutions.

Swing Therapeutics

Swing Therapeutics was founded in 2019 with the goal of developing digital treatments in disease areas where patients are not well-served, and where digital interventions may be effective.

Selventa

Selventa is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bionova Holding Corp

Bionova Holding Corporation acts as a holding company for Agrobionova, S.A. de C.V. (ABSA), of which it owns 98.6%, International Produce Holding Company (IPHC), which is wholly owned, DNA Plant Technology Corporation (DNAP), a wholly owned entity, and

Diasome Pharmaceuticals Inc

Diasome Pharmaceuticals, Inc. is focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity.